Each year, 1.7 billion citizens of developing countries need treatment for neglected diseases, according to the World Health Organization’s (WHO) 2016 World Health Statistics. In a dynamic global environment, pharmaceutical companies face myriad obstacles in supplying poverty stricken communities with necessary medicines and vaccines. Shareholders often question such pursuits, as the cost-benefit matrix of developing…
The pharmaceutical R&D environment has become increasingly challenging due to rising costs, inefficient and complex drug development, high attrition and long regulatory review cycles. The success rate in bringing new drugs to market is rather low, with only about 11.3% of drugs that enter human trials receiving marketing approval, according to the Center for the…
Recent Comments